

Lead Product(s) : Vociprotafib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Revolution Medicines | Mirati Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SAR442720 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 05, 2020
Lead Product(s) : Vociprotafib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Revolution Medicines | Mirati Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Vociprotafib,Sotorasib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Sanofi
Deal Size : $550.0 million
Deal Type : Termination
Sanofi Terminated the Collaboration with Revolution Medicines
Details : SHP2 (PTPN11), a cellular enzyme in the protein tyrosine phosphatase family, plays an important role in multiple forms of cancer and in regulating the immune system.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $50.0 million
December 07, 2022
Lead Product(s) : Vociprotafib,Sotorasib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Sanofi
Deal Size : $550.0 million
Deal Type : Termination

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Vociprotafib,Sotorasib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : First patient dosed in global phase 2 clinical trial evaluating the combination of RMC-4630 (SAR442720)and lumakras™ (sotorasib) in patients with advanced non-small-cell lung cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 11, 2022
Lead Product(s) : Vociprotafib,Sotorasib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Adagrasib,Vociprotafib
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the terms of the agreement, Sanofi will be responsible for sponsoring and operating the Phase 1/2 study, and jointly with Mirati, will oversee and share costs of the study.
Product Name : Krazati
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 07, 2021
Lead Product(s) : Adagrasib,Vociprotafib
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Vociprotafib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Sanofi | Amgen Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RMC-4630 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 23, 2021
Lead Product(s) : Vociprotafib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Sanofi | Amgen Inc
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Vociprotafib,Cobimetinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The ongoing Phase 1b/2 RMC-4630-02 trial is designed to evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of RMC-4630 and cobimetinib in adult patients with relapsed/refractory solid tumors that harbor specific genomic mut...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 12, 2020
Lead Product(s) : Vociprotafib,Cobimetinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Vociprotafib,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Revolution Medicines dosed first patient in a multicenter Phase 1 clinical trial evaluating the combination of RMC-4630 (SAR442720), the company’s investigational SHP2 inhibitor, and pembrolizumab (Keytruda®), an anti-PD-1 antibody.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 22, 2020
Lead Product(s) : Vociprotafib,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Vociprotafib,Sotorasib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Amgen Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The trial is an open-label, dose-escalation and dose-expansion study evaluating the safety, tolerability, pharmacokinetics, and efficacy of the combination of RMC-4630 and AMG 510 in patients with advanced solid tumors harboring the KRASG12C mutation.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 09, 2020
Lead Product(s) : Vociprotafib,Sotorasib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Amgen Inc
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Vociprotafib,Cobimetinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Findings Support Plans to Expand Clinical Evaluation of RMC-4630, the Company’s Investigational SHP2 Inhibitor, to Include Combination with Anti-PD-1 Drug .
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 29, 2020
Lead Product(s) : Vociprotafib,Cobimetinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Vociprotafib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : $100.0 million
Deal Type : Public Offering
Revolution Med shoots for $100M+ IPO — and divulges some secrets about that Warp Drive buyout
Details : Revolution Medicine positioned to expand the horizon on KRAS with 4 programs. KRASG12C, KRASG13C, KRASG12D and NRASG12C with the first development candidate coming up this year.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 18, 2020
Lead Product(s) : Vociprotafib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : $100.0 million
Deal Type : Public Offering



